Non-alcoholic fatty liver disease: relation to juvenile obesity, lipid profile, and hepatic enzymes

Abstract

The prevalence of juvenile obesity is increasing, reaching epidemic proportions, presenting a link not only to NAFLD (non-alcoholic fatty liver disease) but to abnormal lipid profiles and liver enzyme abnormalities. Liver ultrasonography is a sensitive and specific tool for the recognition of NAFLD. This study aims to assess the association between NAFLD and juvenile obesity and to determine the other related changes in a set of indicators, including lipid profile abnormalities and serum transaminases. The sample included 470 obese and 210 non-obese individuals aged 6–16. Anthropometric measures were assessed, with the serum lipid profile and liver transaminases, and abdominal ultrasonography was used to detect NAFLD. Fatty liver was found in 38% of the obese subjects and none of the non-obese subjects. Within obese subjects, mean body mass index (BMI) and waist circumference increased significantly in patients with NAFLD compared to those without fatty liver. Moreover, LDL (low-density lipoprotein), CHOL (cholesterol), and serum liver enzymes were significantly higher in the presence of NAFLD. In conclusion, NAFLD commonly associates with juvenile obesity, relating to obesity and the abnormal lipid profile (including elevated CHOL and LDL) among obese people, reflecting elevated liver transaminases, which increase the risk of cirrhosis.

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq

“…However, further research is needed to determine the most appropriate strategies for implementing pharmacogenetic testing in clinical practice and to evaluate the clinical and economic benefits of these strategies. [ 53 , 54 ]…”

“…in their study recruiting 400 Iraqi healthy individuals of Arab, Kurd, and Turkmen ethnicity found these alleles heterozygotes of CYP2C9 * 2 in 0.19%, CYP2C9 * 3 in 0.14%, and CYP2C9 * 5 in 0.01%. [ 23 , 24 ] Abd Alridha AM et al . [ 25 ] found only two alleles CYP2C9 * 2 in 13.7% and CYP2C9 * 3 in 9.4% in their study including 80 patients of cardiovascular diseases.…”

Protective effect of activated charcoal against progression of chronic kidney disease: A randomized clinical study

“…Limiting protein intake can reduce indoxyl sulfate production, and a low-protein diet supplemented with keto analogues has been shown to decrease serum indoxyl sulfate levels. Administration of activated charcoal has also been reported to lower indoxyl sulfate plasma levels in CKD patients [33][34][35][36].…”

Potential anti-obesity effects of two-graded doses of Iraqi Hibiscus tiliaceus leaves extract, alone and in combination with orlistat, on high-fat diet-induced obesity in male rats

“…tiliaceus was employed as a febrifuge, laxative, resolvent, and emollient in Indian medicine. Its fruit juice has been applied to the skin to treat weakness [13][14][15]. This research investigated the possible anti-obesity effects of two-graded doses of Iraqi Hibiscus tiliaceus leaves extract, alone and in combination with orlistat, on high-fat diet-induced obesity in male rats [16][17][18][19].…”